{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:45:49Z","timestamp":1795088749813,"version":"4.10.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15696-x","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:03:56Z","timestamp":1770440636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5713-004X","authenticated-orcid":false,"given":"Huseyin Ali","family":"Ozturk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3000-4200","authenticated-orcid":false,"given":"Mevlut","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-2771","authenticated-orcid":false,"given":"Ramazan Azim","family":"Okyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7418-5851","authenticated-orcid":false,"given":"Dilan Damla","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0026-2396","authenticated-orcid":false,"given":"Erdinc","family":"Gulumsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6356-9059","authenticated-orcid":false,"given":"Mahmut","family":"Buyuksimsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-917X","authenticated-orcid":false,"given":"Mehmet","family":"Turker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5232-8466","authenticated-orcid":false,"given":"Abdullah Eren","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1160-2125","authenticated-orcid":false,"given":"Fatih Necip","family":"Arici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-0280","authenticated-orcid":false,"given":"Hilmi Erdem","family":"Sumbul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"4","key":"15696_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/wvn.12245","volume":"14","author":"S Secginli","year":"2017","unstructured":"Secginli S, Nahcivan NO, Gunes G, Fernandez R. Interventions promoting breast cancer screening among Turkish women with global implications: A systematic review. Worldviews Evid Based Nurs. 2017;14(4):316\u201323. https:\/\/doi.org\/10.1111\/wvn.12245.","journal-title":"Worldviews Evid Based Nurs"},{"issue":"Suppl 4","key":"15696_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","volume":"54","author":"GN Hortob\u00e1gyi","year":"1997","unstructured":"Hortob\u00e1gyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997;54(Suppl 4):1\u20137. https:\/\/doi.org\/10.2165\/00003495-199700544-00003.","journal-title":"Drugs"},{"issue":"25 Pt A","key":"15696_CR3","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.073.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"15696_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"12","key":"15696_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"key":"15696_CR6","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. (2010). Diagnosis and classification of diabetes mellitus. Diabetes care, 33 Suppl 1(Suppl 1), S62\u2013S69. https:\/\/doi.org\/10.2337\/dc10-S062","DOI":"10.2337\/dc10-S062"},{"issue":"6","key":"15696_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691\u2013722. https:\/\/doi.org\/10.6004\/jnccn.2022.0030.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"15696_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","volume":"52","author":"Y Octavia","year":"2012","unstructured":"Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213\u201325. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.03.006.","journal-title":"J Mol Cell Cardiol"},{"issue":"8","key":"15696_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893\u2013911. https:\/\/doi.org\/10.1200\/JCO.2016.70.5400.","journal-title":"J Clin Oncol"},{"issue":"9","key":"15696_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2014;27(9):911\u201339. https:\/\/doi.org\/10.1016\/j.echo.2014.07.012.","journal-title":"J Am Soc Echocardiogr"},{"key":"15696_CR11","doi-asserted-by":"publisher","unstructured":"Alsereidi FR, Khashim Z, Marzook H et al. Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived \u03b2 cells. Cardiovasc Diabetol. 2024;23(1):388. https:\/\/doi.org\/10.1186\/s12933-024-02481-y.","DOI":"10.1186\/s12933-024-02481-y"},{"issue":"10","key":"15696_CR12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317. https:\/\/doi.org\/10.1007\/s00125-018-4670-7.","journal-title":"Diabetologia"},{"key":"15696_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.01.035.","journal-title":"Free Radic Biol Med"},{"issue":"15","key":"15696_CR14","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"17","key":"15696_CR15","doi-asserted-by":"publisher","first-page":"10146","DOI":"10.3390\/ijms231710146","volume":"23","author":"PL Hsieh","year":"2022","unstructured":"Hsieh PL, Chu PM, Cheng HC, et al. Dapagliflozin mitigates Doxorubicin-Caused myocardium damage by regulating AKT-Mediated oxidative Stress, cardiac Remodeling, and inflammation. Int J Mol Sci. 2022;23(17):10146. https:\/\/doi.org\/10.3390\/ijms231710146.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"15696_CR16","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00204-022-03298-y","volume":"96","author":"WT Chang","year":"2022","unstructured":"Chang WT, Shih JY, Lin YW, et al. Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3. Arch Toxicol. 2022;96(7):2021\u201332. https:\/\/doi.org\/10.1007\/s00204-022-03298-y.","journal-title":"Arch Toxicol"},{"key":"15696_CR17","doi-asserted-by":"publisher","unstructured":"V\u00e1squez-Tirado GA, Meregildo-Rodr\u00edguez ED, Quispe-Casta\u00f1eda CV, et al. Role of SGLT2 inhibitors in cancer therapy-related cardiac dysfunction (CTRCD) in adults: systematic review and meta-analysis: SGLT2 inhibitors and CTRCD. Naunyn schmiedebergs arch Pharmacol. 2025;1. https:\/\/doi.org\/10.1007\/s00210-025-04489-x.","DOI":"10.1007\/s00210-025-04489-x"},{"issue":"1","key":"15696_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40959-024-00284-4","volume":"11","author":"C Simela","year":"2025","unstructured":"Simela C, Walker JM, Ghosh AK, Chen DH. SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights. Cardiooncology. 2025;11(1):15. https:\/\/doi.org\/10.1186\/s40959-024-00284-4.","journal-title":"Cardiooncology"},{"issue":"4","key":"15696_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/hearts5040039","volume":"5","author":"L Piras","year":"2024","unstructured":"Piras L, Zuccanti M, Tini Melato G, Volpe M, Tocci G, Barbato E, Battistoni A. Double duty: SGLT2 inhibitors as cardioprotective and anticancer allies. Hearts. 2024;5(4):529\u201346. https:\/\/doi.org\/10.3390\/hearts5040039.","journal-title":"Hearts"},{"issue":"11","key":"15696_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology study group of the heart failure association of the European society of cardiology in collaboration with the international Cardio-Oncology society. Eur J Heart Fail. 2020;22(11):1945\u201360. https:\/\/doi.org\/10.1002\/ejhf.1920.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"15696_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to Pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2009.03.095.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"15696_CR22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","volume":"6","author":"AW Bhatti","year":"2024","unstructured":"Bhatti AW, Patel R, Dani SS, et al. SGLT2i and primary prevention of cancer Therapy-Related cardiac dysfunction in patients with diabetes. JACC CardioOncol. 2024;6(6):863\u201375. https:\/\/doi.org\/10.1016\/j.jaccao.2024.08.001.","journal-title":"JACC CardioOncol"},{"issue":"8","key":"15696_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","volume":"10","author":"CA Gongora","year":"2022","unstructured":"Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, et al. Sodium-Glucose Co-Transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022;10(8):559\u201367. https:\/\/doi.org\/10.1016\/j.jchf.2022.03.006.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"15696_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","volume":"6","author":"MS Dabour","year":"2024","unstructured":"Dabour MS, George MY, Daniel MR, Blaes AH, Zordoky BN. The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol. 2024;6(2):159\u201382. https:\/\/doi.org\/10.1016\/j.jaccao.2024.01.007.","journal-title":"JACC CardioOncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15696-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15696-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15696-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:33:29Z","timestamp":1773398009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15696-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15696"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15696-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Adana City Training and Research Hospital Ethics Committee approved the study. All participants were informed about the objectives, procedures, risks, and benefits of the study. Written informed consent was obtained from each participant prior to enrollment. This manuscript was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"342"}}